NEUP
Neuphoria Therapeutics Inc. - Common Stock (NEUP)
$82
About Neuphoria Therapeutics Inc. - Common Stock (NEUP)
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded in 1996 and is headquartered in Millis, MA.
Details
Daily high
$2.83
Daily low
$2.73
Price at open
$2.73
52 Week High
$5.53
52 Week Low
$2.70
Market cap
15.0M
Dividend yield
-
Volume
6,979
Avg. volume
35,738
P/E ratio
-.45
Neuphoria Therapeutics Inc. - Common Stock News
Details
Daily high
$2.83
Daily low
$2.73
Price at open
$2.73
52 Week High
$5.53
52 Week Low
$2.70
Market cap
15.0M
Dividend yield
-
Volume
6,979
Avg. volume
35,738
P/E ratio
-.45